Tuesday 13 October 2026
Export CAPR’s income statement to Excel — free account
Capricor Therapeutics, Inc.
CAPR Healthcare Biotechnology
Capricor Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22.3 million, down 11.5% from fiscal 2023. In the quarter to June 2026, revenue fell 7.92%, EPS fell 22.8% and free cash flow fell 72.9%, each against the same quarter a year earlier.
6.88
0.59
−7.90%
Follow CAPR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
3.50 | 8.88 | 8.28 | 7.22 | |
Current Ratio |
3.59 | 9.01 | 8.42 | 7.35 | |
Net Debt/EBITDA |
3.82 | 11.10 | 7.61 | 5.50 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.80 | 0.78 | 0.86 | 0.77 | |
Capex/Depreciation |
(8.10) | 508.40 | (61.06) | 17.54 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.43) | (0.51) | (0.51) | (0.54) | |
Capex per Share |
(0.09) | 5.50 | (0.19) | (0.10) | |
Free Cash Flow per Share |
(0.52) | 4.99 | (0.70) | (0.64) | |
Cash per Share |
2.16 | 6.84 | 4.85 | 4.11 | |
Shareholders Equity per Share |
1.83 | 6.58 | 4.85 | 4.25 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.83 | 6.58 | 4.85 | 4.25 | |
Free Cash Flow |
(23.70) | 231.90 | (40.00) | (37.29) | |
Working Capital |
72.80 | 287.10 | 249.45 | 209.17 | |
Capital Expenditures |
(4.01) | 255.47 | (10.75) | (5.81) | |
Net Current Asset Value |
58.38 | 272.78 | 235.51 | 119.61 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.23 | 5.21 | — | — | |
Average Payables |
4.63 | 2.47 | 4.59 | 3.95 | |
Average Assets |
109.69 | 263.22 | 240.02 | 251.15 | |
Average Common Equity |
76.07 | 225.63 | 203.17 | 175.60 |
Columns are period end dates